Group 1 - The stock price of Shangrong Medical (002551) closed at 4.32 yuan on September 1, 2025, with an increase of 0.93% and a turnover rate of 3.71% [1] - The net inflow of main funds on September 1 was 134.11 million yuan, accounting for 1.37% of the total transaction amount, while retail investors had a net inflow of 180.89 million yuan, accounting for 1.85% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with significant net outflows from main funds on several days [1] Group 2 - Shangrong Medical's total market value is 3.653 billion yuan, with a net asset of 2.763 billion yuan, and a net profit of -7.7582 million yuan, ranking 96th, 57th, and 103rd in the medical device industry respectively [2] - The company's main revenue for the first half of 2025 was 528 million yuan, a year-on-year decrease of 16.38%, and the net profit attributable to shareholders was -7.7582 million yuan, a decline of 155.31% [2] - The gross profit margin of Shangrong Medical is 16.47%, significantly lower than the industry average of 51.85%, indicating a challenging competitive position [2]

二、公司出席人员 董事长兼总经理梁桂秋先生，独立董事曾江虹女士，财务总监游泳先生，副 总经理兼董事会秘书林立女士。 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-045 深圳市尚荣医疗股份有限公司 关于举行2025年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市尚荣医疗股份有限公司（以下简称"公司"）于2025年8月26日在巨 潮资讯网（www.cninfo.com.cn）披露了《2025年半年度报告》及《2025年半年 度报告摘要》，为便于广大投资者更加全面深入地了解公司经营业绩、发展战略 等情况，公司定于2025年9月2日（星期二）15:00-17:00在"价值在线" （www.ir-online.cn）举办2025年半年度网上业绩说明会，与投资者进行沟通和 交流，广泛听取投资者的意见和建议。 一、业绩说明会召开时间和地点 会议召开时间：2025 年 9 月 2 日（星期二）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 三、投资者参加方式 ...

Core Viewpoint - Shenzhen Shangrong Medical (002551) announced the termination of the "High-end Medical Consumables Industrialization Project" and plans to use the remaining raised funds to permanently supplement working capital [1][2][3] Group 1: Project Termination - The project was initially approved for a total fundraising of 750 million yuan through convertible bonds, with a net amount of 733 million yuan after expenses [2] - As of July 31, 2025, the project had accumulated an investment of 415 million yuan, representing 56.73% of the planned investment [2] - The decision to terminate the project was influenced by intensified market competition and declining profit margins, making the original profit expectations unattainable [3][4] Group 2: Financial Performance - The company has faced significant financial challenges, with a cumulative loss of nearly 400 million yuan over four and a half years [6] - Revenue figures from 2021 to 2024 were 1.79 billion yuan, 1.28 billion yuan, 1.19 billion yuan, and 1.44 billion yuan, showing a year-on-year decline of -21.04%, -28.74%, -6.49%, and an increase of 21.40% respectively [7] - In the first half of 2025, the company reported a revenue of 528 million yuan, a year-on-year decline of 16.38%, and a net loss of 7.76 million yuan, a significant drop of 155.31% compared to the previous year [7] Group 3: Asset Management and Regulatory Scrutiny - The company has been under regulatory scrutiny regarding the use of raised funds, with questions raised about the project's expected benefits and the authenticity of fund usage [4][5] - As of June 30, 2025, the total assets of the company were 3.542 billion yuan, with cash and cash equivalents amounting to 419 million yuan, a decrease of 17% from the beginning of the period [8]

据证券之星公开数据整理，近期尚荣医疗（002551）发布2025年中报。截至本报告期末，公司营业总收 入5.28亿元，同比下降16.38%，归母净利润-775.82万元，同比下降155.31%。按单季度数据看，第二季 度营业总收入2.48亿元，同比下降30.12%，第二季度归母净利润-2172.24万元，同比下降15273.62%。本 报告期尚荣医疗三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达 46.96%。 财务费用变动幅度为104.14%,原因:本期可转换债券到期支付利息增加。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率16.47%，同比增7.8%，净利率-0.86%， 同比减128.95%，销售费用、管理费用、财务费用总计7827.57万元，三费占营收比14.82%，同比增 46.96%，每股净资产3.1元，同比减0.1%，每股经营性现金流0.0元，同比减97.77%，每股收益-0.01元， 同比减155.42% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 6.31亿 ...

Group 1 - The core viewpoint of the article is that Shangrong Medical (002551.SZ) has seen an increase in institutional investor holdings, indicating growing interest in the company [1] - As of August 25, 2025, four institutional investors disclosed holdings in Shangrong Medical, totaling 13.6589 million shares, which represents 1.62% of the company's total share capital [1] - The institutional investor ownership increased by 1.05 percentage points compared to the previous quarter [1] Group 2 - Three public funds were disclosed this period, including Agricultural Bank of China CSI 1000 Index Enhanced A, Everbright Prudential Chengxin Mixed A, and Everbright Prudential Multi-Strategy Smart Selection 18-Month Mixed [1] - Two new foreign institutions disclosed their holdings this period, including Goldman Sachs and Barclays Bank PLC [1] - The foreign institution Morgan Stanley & Co. International PLC was not disclosed in this period compared to the previous quarter [1]

Group 1 - Shangrong Medical plans to terminate the "high-end medical consumables industrialization project" and intends to use the remaining raised funds, estimated at 360 million yuan, to permanently supplement working capital, pending shareholder approval [1] - Zhejiang Medicine reported a net profit of approximately 670 million yuan for the first half of 2025, a year-on-year increase of 113.5%, despite a slight revenue decline of 1.9% to about 4.32 billion yuan, driven by increased demand and prices in the life nutrition product segment [1] - Shuyou Shen reported a net loss of 24.64 million yuan for the first half of 2025, with revenue declining by 31% to 126 million yuan, primarily due to the impact of centralized procurement, medical insurance policies, and market competition [2] Group 2 - Huaxia Eye Hospital achieved a net profit of 280 million yuan in the first half of 2025, a year-on-year growth of 6.2%, with revenue increasing by 4.3% to 2.139 billion yuan, supported by strong performance in refractive and posterior segment projects [3] - Despite a decline in cataract project revenue, Huaxia Eye Hospital's overall business remains resilient, indicating potential for continued stable growth through increased R&D investment and market expansion [3]

Group 1 - Shangrong Medical has decided to terminate its "High-end Medical Consumables Industrialization Project" and will use the remaining raised funds, estimated at 360 million yuan, to permanently supplement working capital, pending shareholder approval [1] - The termination of the project highlights previous strategic missteps, and the company needs to accurately position itself and explore new business opportunities to avoid continued weak performance [1] Group 2 - Zhejiang Medicine reported a net profit of approximately 670 million yuan for the first half of 2025, a year-on-year increase of 113.5%, despite a slight revenue decline of 1.9% to about 4.32 billion yuan [2] - The significant profit increase is attributed to rising demand and prices in the life nutrition product segment, but the company needs to address the revenue decline and progress in innovative drug development to maintain growth [2] Group 3 - Shutaishen reported a revenue decline of 31% to 126 million yuan for the first half of 2025, with a net loss of 24.64 million yuan, worsening from a loss of 342,000 yuan in the same period last year [3] - The revenue drop and increased losses are primarily due to the impact of centralized procurement, medical insurance policies, and market competition on core products, with reduced R&D investment and no commercialization of innovative drugs [3] Group 4 - Huaxia Eye Hospital achieved a net profit of 280 million yuan in the first half of 2025, a year-on-year growth of 6.2%, with total revenue of 2.139 billion yuan, up 4.3% [4] - The growth in revenue and profit is driven by strong performance in refractive and posterior segment projects, although cataract project revenue has declined; the company shows resilience and potential for steady development through increased R&D investment [4]

天眼查商业履历信息显示，深圳市尚荣医疗股份有限公司，成立于1998年，位于深圳市，是一家以从事 专用设备制造业为主的企业。企业注册资本84462.5169万人民币，实缴资本82028.6978万人民币。公司 法定代表人为梁桂秋。 金融界消息 截至2025年8月25日收盘，尚荣医疗（002551）报收于4.59元，下跌0.86%，换手率8.57%， 成交量52.38万手，成交金额2.41亿元。 资金流向方面，今日主力资金净流出3216.13万元，占比成交额13.35%。其中，超大单净流出2598.99万 元、占成交额10.79%，大单净流出617.14万元、占成交额2.56%，中单净流出流入1229.54万元、占成交 额5.1%，小单净流入1986.59万元、占成交额8.24%。 尚荣医疗最新一期业绩显示，截至2025中报，公司营业总收入5.28亿元、同比减少16.38%，归属净利润 775.82万元，同比减少155.31%，扣非净利润1251.87万元，同比减少642.19%，流动比率2.450、速动比 率2.098、资产负债率21.99%。 通过天眼查大数据分析，深圳市尚荣医疗股份有限公司共对外投资了17家 ...

Group 1 - The core point of the article is that Shangrong Medical (SZ 002551) held its eighth board meeting on August 23, 2025, to discuss the proposal for the first extraordinary general meeting of shareholders in 2025 [1] - For the first half of 2025, Shangrong Medical's revenue composition was as follows: medical products accounted for 82.55%, other business income for 8.85%, and hospital logistics management services for 8.61% [1] - As of the report date, Shangrong Medical's market capitalization was 3.9 billion yuan [1] Group 2 - The A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating strong market activity [1] - Major industry players are actively recruiting for autumn positions, with 25 job roles highlighted [1]

该公司主营业务为医疗工程建设和医疗器械产销，涉及医院整体建设、医疗设备供应等业务领域。最新 财报显示，2025年上半年公司营业收入5.28亿元，同比下降16.4%；归母净利润亏损776万元，同比下滑 155.3%。其中医疗服务收入大幅下降67.57%，医疗产品销售收入下降3.56%。 尚荣医疗股价报4.59元，较前一交易日下跌0.86%。盘中最高触及4.66元，最低下探至4.56元，成交量为 52.39万手，成交金额达2.41亿元。 风险提示：以上内容仅供参考，不构成任何投资建议。市场有风险，投资需谨慎。 来源：金融界 从资金流向来看，当日主力资金净流出3216.13万元，近五日累计净流出1.23亿元。公司当前总市值 38.81亿元，市盈率为负值。 ...